The FDA granted approval to Orgovyx, developed by Myovant Sciences Ltd. (MYOV) on December 18, 2020 for the treatment of adult patients with advanced prostate cancer.Orgovyx (relugolix) is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the FDA for men with advanced prostate cancer. It blocks the GnRH receptor, and reduces production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer.Analysts at Evercore ISI expect peak sales of $1 billion for the drug in this indication.Myovant priced the drug at $2,313 for a bottle containing 30-day supply.Most common adverse reactions in patients who received Orgovyx were hot flush, musculoskeletal pain, fatigue, constipation, and diarrhea.